ZYPITAMAG Drug Patent Profile

✉ Email this page to a colleague

▶ Start for $100
Remove trial restrictions

Which patents cover Zypitamag, and when can generic versions of Zypitamag launch?

Zypitamag is a drug marketed by Medicure and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pitavastatin magnesium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zypitamag

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

Summary for ZYPITAMAG

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	11
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for ZYPITAMAG
What excipients (inactive ingredients) are in ZYPITAMAG?	ZYPITAMAG excipients list
DailyMed Link:	ZYPITAMAG at DailyMed

Drug patent expirations by year for ZYPITAMAG

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for ZYPITAMAG

Generic Entry Date for ZYPITAMAG^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 208379 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZYPITAMAG

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ZYPITAMAG

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for ZYPITAMAG

ZYPITAMAG is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZYPITAMAG is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZYPITAMAG

Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZYPITAMAG

See the table below for patents covering ZYPITAMAG around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	2013516459		⤷ Sign Up
World Intellectual Property Organization (WIPO)	2011089623		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration